RetaCalc
Protocol library
SingleInvestigationalMixedLow confidenceSourced

KPV

A short anti-inflammatory peptide with cell and animal evidence. A related oral analogue, K(D)PT, reached a small phase 2a colitis study but is not identical to injectable KPV.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Adults with mild-to-moderate ulcerative colitis

Related oral K(D)PT analogue studied at 20 mg, 50 mg or 100 mg twice daily

This eight-week phase 2a study evaluated a related oral molecule, not injectable KPV and not the listed research formulation.

View source

Evidence summary

A short anti-inflammatory peptide with cell and animal evidence. A related oral analogue, K(D)PT, reached a small phase 2a colitis study but is not identical to injectable KPV.

Protocol basis

The page explicitly separates direct preclinical KPV research from a human trial of the related K(D)PT analogue. That distinction supports only low confidence.

What remains uncertain

A validated KPV formulation, human injectable pharmacokinetics and controlled clinical schedule have not been established.

Warnings and contraindications

K(D)PT clinical data cannot be treated as proof for KPV research vials.
The strongest direct KPV evidence is preclinical.
Oral and injectable exposure cannot be assumed equivalent.